Timothy Daly

Dr. Timothy Daly

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
TDTimothy Daly
Timothy Daly
KKKasper P. Kepp
Kasper P. Kepp
BIBruno P. Imbimbo
Bruno P. Imbimbo

28 October 2023 in Ageing Research Reviews
Verified
Journal Article
Open access
AEAlberto J. Espay
Alberto J. Espay
KHKarl Herrup
Karl Herrup
KKKasper P. Kepp
Kasper P. Kepp
TDTimothy Daly
Timothy Daly
The dominant protein-lowering strategy in Alzheimer's Disease (AD) has failed to provide a clinically-meaningful treatment for patients. We hypothesize that the loss of functional, soluble Aβ42 during the process of aggregation into amyloid is more detrimental to the brain than the corresponding accrual of insoluble amyloid.

1 December 2020 in Theoretical Medicine and Bioethics
Verified
Journal Article
Closed access
PDF file
TDTimothy Daly
Timothy Daly
Ignacio MastroleoIgnacio Mastroleo
Ignacio Mastroleo
David H. GorskiDavid H. Gorski
David H. Gorski
Stephane EpelbaumStephane Epelbaum
Stephane Epelbaum

16 December 2023 in Cerebral Circulation - Cognition and Behavior
Verified
Journal Article
Open access
TDTimothy Daly
Timothy Daly
• Non-pharmacological lifestyle interventions have been proposed as a tool to achieve dementia risk reduction. • Lifestyle modification alone is a surface-level intervention from the point of view of fair and far-reaching dementia prevention. Below the tip of this “iceberg of dementia risk,” there are living conditions and social structures that represent deeper contributions to risk in the population. • Alongside lifestyle modification, activist research and structural interventions are needed to make our society fairer and more dementia-resilient.

11 July 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
JSJaime A. Teixeira da Silva
Jaime A. Teixeira da Silva
TDTimothy Daly
Timothy Daly
JTJens Christoph Türp
Jens Christoph Türp
BSBernhard A Sabel
Bernhard A Sabel
GKGraham Kendall
Graham Kendall
There is a substantial body of scientific literature on the use of third-party services (TPS) by academics to assist as “publication consultants” in scholarly publishing. TPS provide a wide range of scholarly services to research teams that lack the equipment, skills, motivation, or time to produce a paper without external assistance. While services such as language editing, statistical support, or graphic design are common and often legitimate, some TPS also provide illegitimate services and send unsolicited e-mails (spam) to academics offering these services. Such illegitimate types of TPS have the potential to threaten the integrity of the peer-reviewed scientific literature. In extreme cases, for-profit agencies known as “paper mills” even offer fake scientific publications or authorship slots for sale. The use of such illegitimate services as well as the failure to acknowledge their use is an ethical violation in academic publishing, while the failure to declare support for a TPS can be considered a form of contract fraud. We discuss some literature on TPS, highlight services currently offered by ten of the largest commercial publishers and expect authors to be transparent about the use of these services in their publications. From an ethical/moral (i.e., non-commercial) point of view, it is the responsibility of editors, journals, and publishers, and it should be in their best interest to ensure that illegitimate TPS are identified and prohibited, while publisher-employed TPS should be properly disclosed in their publications.

11 March 2021 in Journal of Alzheimer's Disease Reports
Verified
Journal Article
Open access
PDF file
TDTimothy Daly
Timothy Daly
MHMarion Houot
Marion Houot
ABAnouk Barberousse
Anouk Barberousse
APAmélie Petit
Amélie Petit
SEStéphane Epelbaum
Stéphane Epelbaum
Background: Therapeutic research into Alzheimer’s disease (AD) has been dominated by the amyloid cascade hypothesis (ACH) since the 1990s. However, targeting amyloid in AD patients has not yet resulted in highly significant disease-modifying effects. Furthermore, other promising theories of AD etiology exist. Objective: We sought to directly investigate whether the ACH still dominates the opinions of researchers working on AD and explore the implications of this question for future directions of research. Methods: During 2019, we undertook an international survey promoted with the help of the Alzheimer’s Association with questions on theories and treatments of AD. Further efforts to promote a similar study in 2021 did not recruit a significant number of participants. Results: 173 researchers took part in the 2019 survey, 22% of which held “pro-ACH” opinions, tended to have more publications, were more likely to be male, and over 60. Thus, pro-ACH may now be a minority opinion in the field but is nevertheless the hypothesis on which the most clinical trials are based, suggestive of a representation bias. Popular vote of all 173 participants suggested that lifestyle treatments and anti-tau drugs were a source of more therapeutic optimism than anti-amyloid treatments. Conclusion: We propose a more democratic research structure which increases the likelihood that promising theories are published and funded fairly, promotes a broader scientific view of AD, and reduces the larger community’s dependence on a fragile economic model.